Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $0.84 and last traded at $0.92, with a volume of 227000 shares trading hands. The stock had previously closed at $0.92.
A number of equities analysts have recently commented on the stock. ValuEngine upgraded shares of Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th.
The company has a market cap of $17.81, a PE ratio of -0.09 and a beta of 2.07. The company has a current ratio of 2.00, a quick ratio of 1.71 and a debt-to-equity ratio of -2.75.
A hedge fund recently raised its stake in Orexigen Therapeutics stock. Wells Fargo & Company MN raised its stake in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,638 shares of the biopharmaceutical company’s stock after purchasing an additional 1,100 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Orexigen Therapeutics worth $132,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.86% of the stock is currently owned by institutional investors.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.